Austrian biotech Proxygen has announced a multi-year collaboration and license agreement with US drugmaker Merck & Co to identify and develop molecular glue degraders...
Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has signed another order worth more than 500 million Swiss francs – or $531...
Pfizer is in the early stage of talks to acquire Seagen (formerly Seattle Genetics), a US biotech focused on developing treatments for cancer, according to a report in...
Solvay’s venture capital fund has joined the Genesis Consortium, a global alliance of venture capital firms and corporations that support startups leveraging...
A new venture capital vehicle launched by a group of biotech entrepreneurs is designed to act as a seed investor as well as a drug discovery co-pilot for biotech startups...
UK specialty chemicals company Croda International has agreed to buy Solus Biotech, a South Korean company specializing in ceramide and phospholipid technologies and with...
Germany‘s Merck has granted an exclusive license for the tumor-targeting IL-12 fusion protein currently known as M9241 to PDS Biotechnology Corporation, a US-based...
AstraZeneca has agreed to acquire Neogene Therapeutics, a clinical-stage biotechnology company focused on the discovery, development and manufacture of next-generation T...
